Search results
Author(s):
Arditya Damarkusuma
Added:
1 year ago
In this video, Dr Arditya Damarkusuma (Universitas Gadjah Mada, ID) presents his case report on aorto-ostial lesions, recently published in ICR Journal.This case covers the restenosis of a markedly protruding stent at the right coronary ostium in a 54-year old man, and is unusual in its 10-year longevity. Intravascular ultrasound-guided in-stent restenosis intervention using a wire bumper…
View more
Author(s):
Jacob Thomsen Lønborg
Added:
9 months ago
EuroPCR 25 - 10-year follow-up findings of DANAMI-3-DEFER show a deferred stenting strategy may reduce HF hospitalisation in ST-elevation myocardial infarction (STEMI) patients.We are joined by Dr Jacob Lønborg (Rigshospitalet, Copenhagen, DK) to discuss key findings from the 10-year follow-up of the DANAMI-3-DEFER (NCT01435408) trial. This randomized controlled trial compared deferred stent…
View more
Author(s):
Roxana Mehran
Added:
1 year ago
EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024.The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary…
View more
Author(s):
Hyo-Soo Kim
Added:
10 months ago
ACC 25 - Findings from a stratified study investigating coronary stenting and bleeding risk suggest 3 months are the optimal duration of DAPT after PCI.Dr Hyo-Soo Kim (Seoul National University Hospital, KR) sits down to discuss the first randomized study stratifying patients receiving percutaneous coronary intervention with drug eluting stents according to bleeding risk based on the ARC HBR…
View more
TCT 23: AGENT IDE
Author(s):
Robert Yeh
Added:
2 years ago
Video
Author(s):
Matthias Bossard
Added:
3 months ago
TCT 2025 - The randomized VICTORY Study finds OCT-guided PCI involving lesion preparation with the OPN super-high-pressure non-compliant balloon is non-inferior to intravascular lithotropsy.Dr Matthias Bossard (Kantonsspital Lucerne, Lucerne, CH) joins us to discuss findings from the VICTORY Trial, a randomized, multicenter, non-inferiority comparison evaluating intravascular lithotripsy versus…
View more
Author(s):
David Erlinge
Added:
3 months ago
TCT 2025 - Findings from INFINITY-SWEDEHEART show significant reductions in target vessel failure and treatment benefit after 6 months to two years with the DynamX bioadaptor stent.Prof David Erlinge (Skane University Hospital, SE) joins us to discuss findings from the INFINITY-SWEDEHEART trial, a prospective, multicenter, registry-based randomized clinical trial comparing long-term outcomes of…
View more
Author(s):
Joost Daemen
,
Nicolas M Van Mieghem
Added:
9 months ago
Dive into our collection covering the hot line and late-breaking trials presented at EuroPCR 2025. Reviewing the sessions you don't want to miss, interventional experts Prof Nicolas Van MieghemandDr Joost Daemen will be leading our regular series View From the Thoraxcenter. For a deeper dive into the most anticipated trials, our Expert Interviews have you covered.
View more
Author(s):
Ajay J Kirtane
Added:
1 year ago
TCT Conference 2024 - Routine use of orbital atherectomy system (OAS) did not improve minimal stent area (MSA) or target vessel failure (TVF) at one year compaared to conventional balloon angioplasty.Dr Ajay J Kirtane (Columbia University Medical Center and New York-Presbyterian Hospital, New York, US) joins us onsite at TCT Conference to discuss the findings from ECLIPSE (NCT03108456; Abbott…
View more
Author(s):
Suzanne J Baron
Added:
3 months ago
TCT 2025 — Dr Suzanne J Baron (Massachusetts General Hospital, US), principal investigator of the Short-CUT trial (NCT06089135; Baim Institute for Clinical Research), joins us to discuss this investigator-initiated, multicentre randomized controlled study.The trial enrolled 410 patients with moderate to severe coronary artery calcification across up to 22 international sites. Eligible…
View more